| 1 |
33471819 | Cabozantinib can block growth of neuroendocrine prostate cancer patient-derived xenografts by disrupting tumor vasculature. | 2021 |
4 |
| 2 |
33525725 | Molecular Modelling Studies on Pyrazole Derivatives for the Design of Potent Rearranged during Transfection Kinase Inhibitors. | 2021 Jan 28 |
1 |
| 3 |
34058344 | Discovery and optimization of selective RET inhibitors via scaffold hopping. | 2021 Sep 1 |
2 |
| 4 |
34117374 | Cabozantinib promotes erythroid differentiation in K562 erythroleukemia cells through global changes in gene expression and JNK activation. | 2021 Jun 11 |
1 |
| 5 |
34445927 | Antitumor effects of the multi-target tyrosine kinase inhibitor cabozantinib: a comprehensive review of the preclinical evidence. | 2021 Sep |
2 |
| 6 |
34497761 | Targeted Therapy for RET Fusion Lung Cancer: Breakthrough and Unresolved Issue. | 2021 |
1 |
| 7 |
34733735 | Case report: identification of ERC1-RET fusion in a patient with pancreatic ductal adenocarcinoma. | 2021 Sep |
1 |
| 8 |
34826838 | [Medullary thyroid carcinoma: current clinical progress]. | 2021 Nov |
1 |
| 9 |
34830178 | Cabozantinib Is Effective in Melanoma Brain Metastasis Cell Lines and Affects Key Signaling Pathways. | 2021 Nov 14 |
3 |
| 10 |
34834190 | Discovery of a Potent Candidate for RET-Specific Non-Small-Cell Lung Cancer-A Combined In Silico and In Vitro Strategy. | 2021 Oct 24 |
1 |
| 11 |
31900481 | Objective Response and Prolonged Disease Control of Advanced Adrenocortical Carcinoma with Cabozantinib. | 2020 May 1 |
2 |
| 12 |
32083304 | Characteristics and outcomes of RET-rearranged Korean non-small cell lung cancer patients in real-world practice. | 2020 May 5 |
1 |
| 13 |
32083997 | State-of-the-Art Strategies for Targeting RET-Dependent Cancers. | 2020 Apr 10 |
2 |
| 14 |
32100934 | Efficacy of Cabozantinib and Nivolumab in Treating Hepatocellular Carcinoma with RET Amplification, High Tumor Mutational Burden, and PD-L1 Expression. | 2020 Jun |
3 |
| 15 |
32463152 | A Phase II Trial of Cabozantinib in Hormone Receptor-Positive Breast Cancer with Bone Metastases. | 2020 Aug |
1 |
| 16 |
32532875 | Case report for an adolescent with germline RET mutation and alveolar rhabdomyosarcoma. | 2020 Jun |
1 |
| 17 |
32645282 | Cabozantinib in patients with platinum-refractory metastatic urothelial carcinoma: an open-label, single-centre, phase 2 trial. | 2020 Aug |
1 |
| 18 |
32671719 | Cabozantinib for the Treatment of Advanced Hepatocellular Carcinoma: Current Data and Future Perspectives. | 2020 Aug |
2 |
| 19 |
32718536 | Identification of a Novel KIF5B-RET, ABHD17C-RET Double-Fusion Variant in Lung Adenocarcinoma and Response to Cabozantinib. | 2020 Aug |
2 |
| 20 |
32835580 | Enhanced antitumor effect of alectinib in combination with cyclin-dependent kinase 4/6 inhibitor against RET-fusion-positive non-small cell lung cancer cells. | 2020 Sep 1 |
2 |
| 21 |
32846061 | Efficacy of Selpercatinib in RET-Altered Thyroid Cancers. | 2020 Aug 27 |
1 |
| 22 |
33318047 | RET inhibition in novel patient-derived models of RET-fusion positive lung adenocarcinoma reveals a role for MYC upregulation. | 2020 Dec 14 |
3 |
| 23 |
30131091 | Clinical Characteristics and Molecular Patterns of RET-Rearranged Lung Cancer in Chinese Patients. | 2019 May 7 |
1 |
| 24 |
30528315 | Results of a Phase II Placebo-controlled Randomized Discontinuation Trial of Cabozantinib in Patients with Non-small-cell Lung Carcinoma. | 2019 Mar |
1 |
| 25 |
30587441 | A randomized phase II study of cabozantinib versus weekly paclitaxel in the treatment of persistent or recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer: An NRG Oncology/Gynecologic Oncology Group study. | 2019 Mar |
1 |
| 26 |
30653139 | RET fusion in advanced non-small-cell lung cancer and response to cabozantinib: A case report. | 2019 Jan |
2 |
| 27 |
30718102 | Phase 1 Study of Cabozantinib in Japanese Patients With Expansion Cohorts in Non-Small-Cell Lung Cancer. | 2019 May |
1 |
| 28 |
30929576 | RET Kinase-Regulated MicroRNA-153-3p Improves Therapeutic Efficacy in Medullary Thyroid Carcinoma. | 2019 Jun |
1 |
| 29 |
30935646 | Reversible Cabozantinib-Induced Cardiomyopathy. | 2019 Apr |
1 |
| 30 |
32914006 | Use of Cabozantinib in a Patient With EGFR-Mutated Non-Small-Cell Lung Cancer Harboring Acquired CCDC6-RET Fusion. | 2019 |
1 |
| 31 |
29284153 | Role of RET protein-tyrosine kinase inhibitors in the treatment RET-driven thyroid and lung cancers. | 2018 Feb |
1 |
| 32 |
29571998 | Identification of a novel KIF13A-RET fusion in lung adenocarcinoma by next-generation sequencing. | 2018 Apr |
1 |
| 33 |
29662541 | Cabozantinib in the treatment of advanced renal cell carcinoma in adults following prior vascular endothelial growth factor targeted therapy: clinical trial evidence and experience. | 2018 Mar |
1 |
| 34 |
29908090 | Drug resistance profiles of mutations in the RET kinase domain. | 2018 Sep |
1 |
| 35 |
30069760 | Cabozantinib: Multi-kinase Inhibitor of MET, AXL, RET, and VEGFR2. | 2018 |
2 |
| 36 |
30210625 | NCOA4-RET fusion in colorectal cancer: Therapeutic challenge using patient-derived tumor cell lines. | 2018 |
1 |
| 37 |
30257958 | Landscape of Acquired Resistance to Osimertinib in EGFR-Mutant NSCLC and Clinical Validation of Combined EGFR and RET Inhibition with Osimertinib and BLU-667 for Acquired RET Fusion. | 2018 Dec |
2 |
| 38 |
30446652 | RET rearrangements are actionable alterations in breast cancer. | 2018 Nov 16 |
1 |
| 39 |
27842445 | Cabozantinib in genitourinary malignancies. | 2017 Apr |
1 |
| 40 |
27922668 | Dual inhibition using cabozantinib overcomes HGF/MET signaling mediated resistance to pan-VEGFR inhibition in orthotopic and metastatic neuroblastoma tumors. | 2017 Jan |
1 |
| 41 |
28477875 | [Cabozantinib: Mechanism of action, efficacy and indications]. | 2017 May |
2 |
| 42 |
28650002 | Cabozantinib use in renal cell carcinoma. | 2017 May |
1 |
| 43 |
28703624 | Cabozantinib in the treatment of hepatocellular carcinoma. | 2017 Sep |
1 |
| 44 |
29045520 | Overall survival analysis of EXAM, a phase III trial of cabozantinib in patients with radiographically progressive medullary thyroid carcinoma. | 2017 Nov 1 |
4 |
| 45 |
29059635 | Phase II randomised discontinuation trial of cabozantinib in patients with advanced solid tumours. | 2017 Nov |
1 |
| 46 |
29088743 | In vitro and in vivo anti-tumor activity of alectinib in tumor cells with NCOA4-RET. | 2017 Sep 26 |
2 |
| 47 |
26536165 | Cabozantinib for the treatment of progressive metastatic medullary thyroid cancer. | 2016 |
3 |
| 48 |
26652860 | A Pyrazolo[3,4-d]pyrimidin-4-amine Derivative Containing an Isoxazole Moiety Is a Selective and Potent Inhibitor of RET Gatekeeper Mutants. | 2016 Jan 14 |
2 |
| 49 |
26973202 | ALK, ROS1 and RET rearrangements in lung squamous cell carcinoma are very rare. | 2016 Apr |
2 |
| 50 |
27429741 | Identification of selective inhibitors of RET and comparison with current clinical candidates through development and validation of a robust screening cascade. | 2016 |
1 |